摘要
目的总结近年来胰腺癌新辅助化疗的治疗现状及进展,以期提高对胰腺癌新辅助化疗的认识,并指导临床工作。方法通过阅读并复习国内外有关胰腺癌新辅助化疗方面的文献并进行综述。结果新辅助化疗可缩小肿瘤病灶、提高R0切除率、降低术后并发症发生率且改善患者的预后,但目前尚缺乏高质量的循证医学证据。目前国际上并无统一的胰腺癌新辅助化疗方案,FOLFIRINOX、吉西他滨+白蛋白结合型紫杉醇和吉西他滨+替吉奥3种方案较为常见。同时,新辅助化疗存在化疗方案无统一标准、疗效评估手段不足等问题。结论尽管胰腺癌的新辅助化疗尚存在一些核心问题亟待解决,但其显示出的疗效正逐渐被临床工作者所认可并广泛应用,这有利于改善胰腺癌患者的预后。
Objective To summarize the current treatment status and progress of neoadjuvant chemotherapy for pancreatic cancer in order to improve the understanding of neoadjuvant chemotherapy and to guide clinical work.Method The relevant literatures at home and abroad on neoadjuvant chemotherapy for pancreatic cancer were readed and reviewed. Results Neoadjuvant chemotherapy could reduce tumor lesions, increase R0 resection rate, decrease postoperative complication rate, and improve patients’ survival, however, there was currently no high quality evidencebased medicine proof. At present, there was no unified neoadjuvant chemotherapy regimens for pancreatic cancer in the world. FOLFIRINOX, gemcitabine plus S-1, and gencitabine plus Nab-paclitaxel were the three common regimens we used. In addition, the neoadjuvant chemotherapy of pancreatic cancer had no uniform standard, and there were insufficient methods for evaluating therapeutic effects. Conclusion Although there are still some core problems need to be solved in neoadjuvant chemotherapy for pancreatic cancer, however, it’s curative effect is gradually recognized and widely used by clinicians, which is beneficial to provide a better prognosis for pancreatic cancer patients.
作者
奚士航
王小明
XI Shihang;WANG Xiaoming(Department of Hepatobiliary Surgery,The First Affiliated Hospital of Wannan Medical College,Wuhu,Anhui 241000,P.R.China)
出处
《中国普外基础与临床杂志》
CAS
2020年第2期226-231,共6页
Chinese Journal of Bases and Clinics In General Surgery
基金
安徽省中央引导地方科技发展专项项目(项目编号:YDZX20183400004899)
安徽省科学技术攻关基金资助项目(项目编号:1501041156)
关键词
胰腺癌
新辅助化疗
方案选择
疗效评估
综述
pancreatic cancer
neoadjuvant chemotherapy
regimen selection
efficacy assessment
review
